Quarterly ResultMay 5, 2026, 07:08 AM
Orthofix Q1 Net Loss Narrows to $(20.9)M; EPS $(0.52)
AI Summary
Orthofix Medical Inc. reported a significant narrowing of its net loss for Q1 2026 to $(20.9) million, a 60.6% improvement year-over-year, with basic EPS improving to $(0.52). Net sales increased by 1.6% to $196.7 million, driven by strong growth in Global Limb Reconstruction and Therapeutic Solutions. The company also resolved arbitration claims with former executives, accruing $23.3 million for these matters, and drew $65.0 million from its Term B Loan facility.
Key Highlights
- Net loss significantly narrowed to $(20.9) million, a 60.6% improvement from $(53.1) million year-over-year.
- Basic net loss per common share improved to $(0.52) from $(1.35) in the prior year period.
- Net sales increased by 1.6% to $196.7 million for the three months ended March 31, 2026.
- Global Limb Reconstruction segment sales grew by 10.2% to $32.9 million.
- Therapeutic Solutions segment sales increased by 4.9% to $57.8 million.
- Resolved arbitration claims with former executives, accruing $23.3 million as of March 31, 2026.
- Borrowed $65.0 million via the Term B Loan, increasing long-term debt to $221.3 million.
- Cash and cash equivalents increased to $120.3 million from $82.0 million at year-end 2025.
Price Impact
More from OFIX